Holen Sie sich die Stockscreener-App
0.2497
0.36%
-0.0015
Schlusskurs vom Vortag:
$0.2482
Offen:
$0.2478
24-Stunden-Volumen:
21,721
Relative Volume:
0.05
Marktkapitalisierung:
$16.11M
Einnahmen:
$1.16M
Nettoeinkommen (Verlust:
$-39.74M
KGV:
-0.4027
EPS:
-0.62
Netto-Cashflow:
$-35.02M
1W Leistung:
-1.00%
1M Leistung:
+9.18%
6M Leistung:
-21.94%
1J Leistung:
-12.40%
1-Tages-Spanne:
$0.2446
$0.2514
1-Wochen-Bereich:
$0.233
$0.275
52-Wochen-Spanne:
$0.1406
$0.63
Glycomimetics Inc Stock (GLYC) Company Profile
Firmenname
Glycomimetics Inc
Sektor
Branche
Telefon
240-243-1201
Adresse
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Vergleichen Sie GLYC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLYC
Glycomimetics Inc
|
0.2497 | 15.42M | 1.16M | -39.74M | -35.02M | -0.62 |
|
ONC
Beigene Ltd Adr
|
238.53 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.43 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.24 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.96 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.85 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-26 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-22 | Eingeleitet | CapitalOne | Overweight |
| 2021-11-12 | Hochstufung | Jefferies | Hold → Buy |
| 2019-11-14 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-05 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-12-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-07-26 | Eingeleitet | SunTrust | Buy |
| 2015-03-17 | Bestätigt | Stifel | Buy |
Alle ansehen
Glycomimetics Inc Aktie (GLYC) Neueste Nachrichten
GlycoMimetics executives to depart amid merger plans - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NDOI, SSBK, BRDG on Behalf of Shareholders - GlobeNewswire Inc.
GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com - Defense World
GlycoMimetics (NASDAQ:GLYC) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World
GlycoMimetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc.GLYC - marketscreener.com
GlycoMimetics: Q1 Earnings Snapshot - The Washington Post
GLYCOMIMETICS INC SEC 10-Q Report - TradingView
StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics, Inc. to Host Earnings Call - ACCESS Newswire
$TOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The MergerGLYC, BRZH, PRA, FVNNU - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COLB, PRA, GLYC on Behalf of Shareholders - Finansavisen
A Stock Analysis Of GlycoMimetics Inc’s (GLYC) - Stocksregister
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com - Defense World
Ratios Revealed: Decoding GlycoMimetics Inc (GLYC)’s Financial Health - DWinneX
GlycoMimetics Inc (GLYC Stock: A Sea of Opportunity - investchronicle.com
Cantor Fitzgerald initates GlycoMimetics Inc (GLYC) rating to an Overweight - knoxdaily.com
GlycoMimetics Amends Merger Agreement With Crescent Biopharma - Investing.com
GlycoMimetics, Inc. (GLYC) Stock Report: Analyst Ratings Signal Potential in Biotech Space - DirectorsTalk Interviews
Press Release Distribution & PR Platform - ACCESS Newswire
A Look at GlycoMimetics Inc (GLYC) Shares in the Recent Past Indicates Growth - Sete News
GLYC Shares Experience Surge in Value - knoxdaily.com
GlycoMimetics (NASDAQ:GLYC) Stock Price Passes Below 200 Day Moving Average – Time to Sell? - Defense World
GlycoMimetics Inc (GLYC) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Understanding GLYC stock ratios for better investment decisions - uspostnews.com
GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World
Wellington Management Group LLP Makes New Investment in GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World
GlycoMimetics, Inc. Announces Efficacy and Safety Data from Phase 1/2 Clinical Study of Uproleselan Published in BLOOD - MarketScreener
Form 425 GLYCOMIMETICS INC Filed by: GLYCOMIMETICS INC - StreetInsider
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics - Quantisnow
GLYCOMIMETICS Earnings Preview: Recent $GLYC Insider Trading, Hedge Fund Activity, and More - Nasdaq
Cantor Fitzgerald Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
Cantor Fitzgerald maintains Overweight on GlycoMimetics stock By Investing.com - Investing.com Australia
Cantor Fitzgerald Initiates Coverage of GlycoMimetics (GLYC) with Overweight Recommendation - MSN
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated by Analysts at StockNews.com - Defense World
Cantor Fitzgerald maintains Overweight on GlycoMimetics stock - Investing.com India
Cantor Fitzgerald Initiates GlycoMimetics at Overweight -March 21, 2025 at 07:18 am EDT - Marketscreener.com
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
GlycoMimetics, Inc. (NASDAQ:GLYC) Short Interest Update - Defense World
Finanzdaten der Glycomimetics Inc-Aktie (GLYC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
3.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):